Skip to content

SLU-PP-332: Side Effects & Safety

Part of the SLU-PP-332 Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Overall Safety Profile

SLU-PP-332 is preclinical only — no human safety data exists. Animal studies did not report significant toxicity over the study durations, but comprehensive safety evaluation has not been performed.

Observed Effects in Animals

  • No significant toxicity reported in published mouse studies
  • Body weight changes: Reduced weight gain on high-fat diet (therapeutic effect)
  • No behavioral abnormalities observed during study periods

Critical Safety Limitations

ERR activation affects multiple organ systems beyond skeletal muscle — cardiac, hepatic, and reproductive effects would need thorough evaluation before human use. ERR signaling plays context-dependent roles in certain cancers, requiring careful safety assessment. No pharmacokinetic, pharmacodynamic, or toxicology studies in humans have been conducted.

Theoretical Contraindications

  • Active cancer (ERR signaling role in tumor biology)
  • Cardiac conditions (ERR affects cardiac metabolism)
  • Pregnancy and breastfeeding
  • No drug interaction data available

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.